Inhibikase Therapeutics Inc. announced the election of Richard Fante, former President of AstraZeneca U.S.A. and CEO of AstraZeneca North America and the election of Patrick Vink, former Executive Vice President and COO of Cubist Pharmaceuticals, to its Board of Directors. Anthony Zook has stepped down from the Board due to his new role as CEO of Innocoll AG. Rich Fante serves as President of RF Consulting LLC since April 11, 2013, a private pharmaceutical consulting business that advises clients on commercial assessments and go-to-market strategies.

Prior to founding RF Consulting, Mr. Fante spent over nineteen years at AstraZeneca Pharmaceuticals in the United States. He served most recently as President U.S.A. and CEO North America and Regional Vice President for the Americas.  Prior to assuming his role as President AstraZeneca U.S.A., Mr. Fante served as the head of Brand Strategy and Portfolio Operations at AstraZeneca. Patrick Vink, M.D., M.B.A., is currently an advisor to the pharmaceutical industry and joins the Inhibikase Board following 3+ years at Cubist Pharmaceuticals, where he served as Executive Vice-President and Chief Operating Officer, overseeing all worldwide commercial and technical operations as well as global alliance management.

He joined Cubist in 2012 as Senior Vice-president and Head of all International Business Operations. In this role he was responsible for the all business activities in International markets outside USA. Prior to joining Cubist, Dr. Vink served as Senior Vice President, Global Head of Hospital Business and Global Head of Biologics for Mylan Inc. In this role, Dr. Vink coordinated all hospital business of the company.